Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Solid Neoplasm: early-phase trial registry
94 of 177 indexed Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #62 of 28,707 conditions by registered trial count.
177 US clinical trials · 94 currently recruiting · #62 of 28,707 conditions by registered trial count
Malignant Solid Neoplasm: 177 US clinical trials tracked, 94 recruiting.
Malignant Solid Neoplasm is the subject of 177 registered US clinical trials on ClinicalTrials.gov, 94 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 42 of these trials.
Enrollment posture brief
Registry condition malignant-solid-neoplasm
OPEN 94 | RECR 53% | LATE 14 | EARLY 46 | RANK #62 | SPON 42
Volume-matched condition peers
Nearest open-share peer: Endometriosis (53% recruiting · 49 trials)
Malignant Solid Neoplasm lists 94 open slots (53% of 177 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Solid Neoplasm is recruiting above its size-band peers.
94 of 177 indexed trials (53.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Solid Neoplasm research.
M.D. Anderson Cancer Center accounts for 42 of 177 trials (23.7%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Malignant Solid Neoplasm enrolment sits around 105 participants.
Median target enrolment is 105 among the 177 trials that report a genuine target (sentinel values excluded). 84 of those (47.5%) plan for fewer than 100 participants.
-
Malignant Solid Neoplasm research is mostly interventional.
128 interventional and 49 observational studies make up this index (72.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
177 total, page 4 of 4
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
National Cancer Institute (NCI)
NCT05142241
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03213652
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT02993146
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
NCT04745910
On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge
City of Hope Medical Center
NCT06625619
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT04284774
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
M.D. Anderson Cancer Center
NCT04743466
Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial
Mayo Clinic
NCT03892967
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
M.D. Anderson Cancer Center
NCT05045963
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
NCT04456140
Perioperative Care in the Cancer Patient -1, ARCA-1 Study
M.D. Anderson Cancer Center
NCT04491409
Food Safety Educational Training Program to Improve Food Safety Knowledge and Behaviors in Cancer Patients Receiving Treatment
Ohio State University Comprehensive Cancer Center
NCT06630442
A Study of Physical Activity in Cancer Survivors
Mayo Clinic
NCT05988892
Evaluation of a Couple-Based Physical Activity Intervention
Mayo Clinic
NCT06073951
Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment
Thomas Jefferson University
NCT04788758
Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer
Emory University
NCT05346692
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
Ohio State University Comprehensive Cancer Center
NCT04602026
Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk
Mayo Clinic
NCT05950399
Development of the Oncology Opportunity Cost Assessment Tool
Thomas Jefferson University
NCT04694911
Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy
OHSU Knight Cancer Institute
NCT04170075
Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit
M.D. Anderson Cancer Center
NCT02686411
Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor
Thomas Jefferson University
NCT04122118
Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy
M.D. Anderson Cancer Center
NCT05083338
Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors
Wake Forest University Health Sciences
NCT06881108
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04439006
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
Fred Hutchinson Cancer Center
NCT04902144
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
NCT04631029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 22 |
| Phase 3 | 12 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Solid Neoplasm page
177 registered trials, 94 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 94 Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Solid Neoplasm condition card totals 177 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.